The information on this website is intended for healthcare professionals only and is provided for the purpose of scientific exchange.
The website is not country specific and may therefore contain information that is not applicable in your country, thus you may find information concerning study drugs or therapeutic uses that have not been approved by drug regulatory agencies. This website is not intended to promote in any way, any use, either approved, or unapproved, of a Novo Nordisk product or of any other product or serve as basis for any treatment decision or action. Please always refer to Summary of Product Characteristics (product label) as approved by regulatory authorities in your country or contact Novo Nordisk for further information.
Furthermore, the site is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. Only a physician can determine whether a specific product is correct for a particular patient. Novo Nordisk accepts no liability for the accuracy, completeness or use of this information, and disclaims any liability to update the information contained on this site.
By accessing this website you accept this legal notice and expressly confirm your status as a healthcare professional.
Domenica Rubino is the founder and Director of the Washington Center for Weight Management & Research in Arlington, VA, USA, a comprehensive weight management programme utilising a multidisciplinary team for the care of the individuals with obesity. Dr Rubino is board certified in Obesity Medicine, Endocrinology, Diabetes & Metabolism, and Internal Medicine and received training in both clinical and molecular biological research at the US National Institutes of Health. She has extensive experience in the care of the overweight patient and has conducted clinical research for the development of pharmaco-therapeutic agents in the management of obesity. She is currently a clinical investigator for AstraZeneca, Boehringer Ingelheim and Novo Nordisk, and is the recipient of an independent research grant from Obesinov, SARL.
She currently serves as a clinical expert on the treatment of obesity for several professional committees, and as a consultant and speaker for Novo Nordisk, and has also served as a representative to Congress and outside organisations for The Obesity Society. She often speaks as an advocate for the person struggling with obesity and has a strong interest in the psychological impact and societal stigma of this medical condition.
Dr Rubino has received several investigator awards, and has and has authored select peer-reviewed publications (including JAMA, Lancet, Obesity, the European Journal of Endocrinology, the Journal of Clinical Endocrinology and Metabolism and Diabetes, Obesity and Metabolism), and recently contributed a chapter on ‘Biopsychosocial Modifiers of Obesity’ for the textbook entitled Bariatric Endocrinology, published by Springer Verlag.